

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-CD105 [huRH105-1] Standard Size Ab04017-10.0

Isotype and Format: Human IgG1, Kappa

Clone Number: huRH105-1

Alternative Name(s) of Target: endoglin; ENG

UniProt Accession Number of Target Protein: P17813

Published Application(s): in vitro, in vivo, FC Published Species Reactivity: Rat, Human

Immunogen: The original mouse parental antibody RH105-1 was generated by intraperitoneal immunization of BALB/c VAF mice with rat CD105-expressing 300-19 cells. This antibody was synthetically engineered to mimic a binding specificity of the original RH105-1, by grafting the CDRs of the parental antibody onto human framework segments.

Specificity: The antibody binds to human and rat endoglin.

Application Notes: This antibody was used for detection of CD105 expressed on Vero cell lines by flow cytometry (Kd = 0.024 nM). The ability of the antibody to induce apoptosis on HUVEC cells was measured. Results showed that treatment with the antibody induced apoptosis of up to 47% of HUVEC cells at a concentration of 0.25 µg/mL. Further, the antibody induced a greater percentage of cells to undergo apoptosis under hypoxic conditions. The binding affinity of the antibody and the antibody conjugated to SPDB-DM4 was assayed by flow cytometry. The value of the apparent dissociation constants were calculated Kd = 1.63 nM and 2.12 nM, respectively. Treatment of HUVEC cells with huRH105-I-SMCC-DMI completely reduced viability of HUVEC cells with an EC50 of 0.12 nM in in vitro cytotoxicity experiments, while treatment of HUVEC cells with huRH105-I-SPDB-DM4 completely reduced viability with an EC50 of 0.21 nM. The antibody bound to Rat Aortic Endothelial Cells (RAOEC) by flow cytometry analysis (Kd = 0.13nM). The ability the conjugate antibodies to inhibit cell growth of RAOEC cells was measured using an in vitro cytotoxicity assay. Treatment with huRH105-l- SMCC-DM1 completely reduced viability of RAOEC cells with an EC50of 0.48 nM for huRH105-l-SMCC-DMI and 1.1 nM for huRH105-l-SPDB-DM4. Analysis of in vivo efficacy of huRH105-I-SMCC-DMI in combination with bevacizumab in A2780 and HCT116 rat xenograft models showed improved efficacy compared to the control experiment. Analysis of in vivo efficacy of huRH105-I-SMCC-DMI alone in an U87MG rat xenograft model showed improved efficacy compared to the control experiment (WO2012149412A2).

Antibody First Published in: PMID:

Note on publication:

Product Form

Size: 100 μg Purified antibody.

Purification: Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.